JPH07505372A - 3−o−脱アシル化モノホスホリル脂質a含有の肝炎ワクチン - Google Patents
3−o−脱アシル化モノホスホリル脂質a含有の肝炎ワクチンInfo
- Publication number
- JPH07505372A JPH07505372A JP5517046A JP51704693A JPH07505372A JP H07505372 A JPH07505372 A JP H07505372A JP 5517046 A JP5517046 A JP 5517046A JP 51704693 A JP51704693 A JP 51704693A JP H07505372 A JPH07505372 A JP H07505372A
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- vaccine
- antigen
- hbsag
- mpl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (20)
- 1.肝炎抗原を3−O−脱アシル化モノホスホリル脂質Aおよび適当な担体と組 み合わせてなるワクチン組成物。
- 2.担体がアラムである請求項1記載のワクチン組成物。
- 3.担体が水中油型エマルジョンまたは他の脂質基材ビヒクルである請求項1記 載のワクチン組成物。
- 4.肝炎抗原がA型肝炎に対する抗原である前記いずれかの請求項に記載のワク チン組成物。
- 5.A型肝炎抗原がHM−175菌株由来の不活化全細胞組成物である請求項4 記載のワクチン組成物。
- 6.肝炎抗原がB型肝炎に対する抗原である請求項1〜3のいずれか1つに記載 のワクチン処方。
- 7.抗原がB型肝炎表面抗原(HBsAg)またはその変異体からなる請求項6 記載のワクチン組成物。
- 8.HBsAgがHBsAgのS抗原(226アミノ酸)からなる請求項7記載 のワクチン組成物。
- 9.HBsAgが、付加的に、プレ−S配列からなる請求項8記載のワクチン組 成物。
- 10.HBsAgが、式(L*,S)の複合粒子であり、ここにし*はし蛋白質 の残基12〜52、つづいて残基133〜145、ついで残基175〜400か らなるアミノ酸配列を有するB型肝炎ウイルスの修飾L蛋白質を意味し、SはH BsAgのS−蛋白質を意味する請求項8または請求項9記載のワクチン組成物 。
- 11.付加的に、A型肝炎抗原からなる請求項6〜10のいずれか1つに記載の ワクチン組成物。
- 12.1種またはそれ以上の肝炎抗原と、1またはそれ以上の次に示す:ジフテ リア、破傷風、百日咳、ヘモフィルス・インフルエンザb(Hib)およびポリ オに対して保護を付与する非肝炎抗原から選択される少なくとも1種の他の成分 とからなる前記いずれかの請求項に記載のワクチン組成物。
- 13.DTP(ジフテリアー破傷風−百日咳)−HBsAgの組み合わせ、Hi b−HBsAgの組み合わせ、DTP−Hib−HBsAgの組み合わせ、およ びIPV(不活化ポリオワクチン)−DTP−Hib−HBsAgの組み合わせ から選択される請求項12記載のワクチン組成物。
- 14.付加的に、A型肝炎抗原からなる請求項12記載のワクチン組成物。
- 15.肝炎抗原がC型肝炎、D型肝炎またはE型肝炎に対する抗原である請求項 1〜3のいずれか1つに記載のワクチン組成物。
- 16.3−O−脱アシル化モノホスホリル脂質Aが一用量当たり10μg〜10 0μgの範囲にて存在する前記いずれかの請求項に記載のワクチン組成物。
- 17.医薬において用いるための前記請求項に記載のワクチン組成物。
- 18.肝炎感染症の予防または治療用の医薬の製造において、3−O−脱アシル 化モノホスホリル脂質Aと組み合わせてなる肝炎抗原の使用。
- 19.肝炎感染症に罹患しているかまたは感受的であるヒト対象の治療法であっ て、有効量の請求項1〜16のいずれか1つのワクチンを投与することからなる 治療法。
- 20.進行中の肝炎感染症に罹患しているヒト対象の治療法であって、有効量の 請求項1〜16のいずれかに記載の治療用ワクチンを投与することからなる治療 法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929206788A GB9206788D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
GB9206788.3 | 1992-03-27 | ||
GB929206797A GB9206797D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
GB9206797.4 | 1992-03-27 | ||
GB929206786A GB9206786D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
GB9206786.7 | 1992-03-27 | ||
GB9206789.1 | 1992-03-27 | ||
GB929206789A GB9206789D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
PCT/EP1993/000712 WO1993019780A1 (en) | 1992-03-27 | 1993-03-24 | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07505372A true JPH07505372A (ja) | 1995-06-15 |
JP3470719B2 JP3470719B2 (ja) | 2003-11-25 |
Family
ID=27450853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51704693A Expired - Lifetime JP3470719B2 (ja) | 1992-03-27 | 1993-03-24 | 3−o−脱アシル化モノホスホリル脂質a含有の肝炎ワクチン |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP0633784B2 (ja) |
JP (1) | JP3470719B2 (ja) |
KR (1) | KR100270134B1 (ja) |
CN (1) | CN1072963C (ja) |
AP (1) | AP570A (ja) |
AT (1) | ATE146678T1 (ja) |
AU (4) | AU3751693A (ja) |
CA (1) | CA2132833C (ja) |
CZ (1) | CZ283424B6 (ja) |
DE (1) | DE69306940T3 (ja) |
DK (1) | DK0633784T4 (ja) |
ES (1) | ES2098029T5 (ja) |
FI (1) | FI110843B (ja) |
GR (1) | GR3022174T3 (ja) |
HK (1) | HK1003218A1 (ja) |
HU (1) | HU221253B1 (ja) |
IL (1) | IL105161A (ja) |
MA (1) | MA22842A1 (ja) |
MY (1) | MY111880A (ja) |
NO (1) | NO309458B1 (ja) |
NZ (1) | NZ249868A (ja) |
RU (1) | RU2121849C1 (ja) |
SA (1) | SA93130573B1 (ja) |
SG (1) | SG48375A1 (ja) |
SI (1) | SI9300149B (ja) |
SK (1) | SK280160B6 (ja) |
UA (1) | UA44688C2 (ja) |
WO (1) | WO1993019780A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002527105A (ja) * | 1998-10-16 | 2002-08-27 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2003508494A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
JP2012121916A (ja) * | 1998-10-16 | 2012-06-28 | Glaxosmithkline Biologicals Sa | ワクチン |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
HU219056B (hu) * | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
DE69933200T2 (de) * | 1998-03-09 | 2007-02-22 | Glaxosmithkline Biologicals S.A. | Kombinierte impfstoffzusammensetzungen |
US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
FI108150B (fi) | 1999-02-15 | 2001-11-30 | Sulzer Pumpen Ag | Menetelmä ja laitteisto massan käsittelemiseksi |
US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
EP2305294B1 (en) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
JP5869744B2 (ja) | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Cd4t細胞および/または改善された記憶b細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
WO2007052155A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
DK1976559T6 (da) | 2006-01-27 | 2020-04-06 | Seqirus Uk Ltd | Influenzavacciner indeholdende hæmagglutinin og matrixproteiner |
ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
EP2476434A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
KR101696727B1 (ko) | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
CA2663196A1 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
EP2687228B1 (en) | 2007-06-26 | 2017-07-19 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CA2710480A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
ES2671880T3 (es) * | 2009-03-05 | 2018-06-11 | Jenny Colleen Mccloskey | Tratamiento de infección |
DK3178490T3 (da) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2646459B1 (en) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
CN103347892B (zh) | 2011-01-06 | 2016-11-02 | 比奥诺尔免疫有限公司 | 单体和多聚体免疫原性肽 |
EP3527224A1 (en) | 2011-01-26 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
EP2859011B1 (en) | 2012-06-06 | 2019-12-11 | Bionor Immuno AS | Peptides derived from viral proteins for use as immunogens and dosage reactants |
US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE70308T1 (de) * | 1984-09-12 | 1991-12-15 | Chiron Corp | Hybridpartikel-immunogene. |
ES2012739T5 (es) * | 1987-11-18 | 2001-12-01 | Chiron Corp | Diagnosticos para nanbv. |
AU3748489A (en) * | 1988-06-17 | 1990-01-12 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
EP0414374B1 (en) * | 1989-07-25 | 1997-10-08 | Smithkline Biologicals S.A. | Novel antigens and methods for their preparation |
JP3156200B2 (ja) * | 1989-09-15 | 2001-04-16 | 国立予防衛生研究所長 | 新規のhcv分離株 |
IL97985A0 (en) * | 1990-05-07 | 1992-06-21 | North American Vaccine Inc | Improved vaccine compositions |
WO1992011291A1 (en) * | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
-
1993
- 1993-03-23 MA MA23137A patent/MA22842A1/fr unknown
- 1993-03-23 MY MYPI93000533A patent/MY111880A/en unknown
- 1993-03-24 RU RU94042386A patent/RU2121849C1/ru active
- 1993-03-24 NZ NZ249868A patent/NZ249868A/en not_active IP Right Cessation
- 1993-03-24 HU HU9402758A patent/HU221253B1/hu unknown
- 1993-03-24 DE DE69306940T patent/DE69306940T3/de not_active Expired - Lifetime
- 1993-03-24 CA CA002132833A patent/CA2132833C/en not_active Expired - Lifetime
- 1993-03-24 AT AT93906601T patent/ATE146678T1/de active
- 1993-03-24 DK DK93906601T patent/DK0633784T4/da active
- 1993-03-24 CZ CZ942355A patent/CZ283424B6/cs not_active IP Right Cessation
- 1993-03-24 SK SK1152-94A patent/SK280160B6/sk not_active IP Right Cessation
- 1993-03-24 ES ES93906601T patent/ES2098029T5/es not_active Expired - Lifetime
- 1993-03-24 WO PCT/EP1993/000712 patent/WO1993019780A1/en active IP Right Grant
- 1993-03-24 UA UA94105947A patent/UA44688C2/uk unknown
- 1993-03-24 AU AU37516/93A patent/AU3751693A/en not_active Abandoned
- 1993-03-24 EP EP93906601A patent/EP0633784B2/en not_active Expired - Lifetime
- 1993-03-24 KR KR1019940703355A patent/KR100270134B1/ko not_active IP Right Cessation
- 1993-03-24 JP JP51704693A patent/JP3470719B2/ja not_active Expired - Lifetime
- 1993-03-24 SG SG1996009183A patent/SG48375A1/en unknown
- 1993-03-25 IL IL10516193A patent/IL105161A/en not_active IP Right Cessation
- 1993-03-25 AP APAP/P/1993/000502A patent/AP570A/en active
- 1993-03-26 SI SI9300149A patent/SI9300149B/sl unknown
- 1993-03-26 CN CN93105232A patent/CN1072963C/zh not_active Expired - Lifetime
- 1993-06-08 SA SA93130573A patent/SA93130573B1/ar unknown
-
1994
- 1994-09-26 NO NO943571A patent/NO309458B1/no not_active IP Right Cessation
- 1994-09-26 FI FI944442A patent/FI110843B/fi not_active IP Right Cessation
-
1996
- 1996-09-05 AU AU64457/96A patent/AU6445796A/en not_active Abandoned
- 1996-12-30 GR GR960403615T patent/GR3022174T3/el unknown
-
1998
- 1998-03-19 HK HK98102341A patent/HK1003218A1/xx unknown
-
1999
- 1999-06-10 AU AU33974/99A patent/AU3397499A/en not_active Abandoned
-
2002
- 2002-01-02 AU AU10008/02A patent/AU767755B2/en not_active Expired
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002527105A (ja) * | 1998-10-16 | 2002-08-27 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2012121916A (ja) * | 1998-10-16 | 2012-06-28 | Glaxosmithkline Biologicals Sa | ワクチン |
JP2003508494A (ja) * | 1999-09-07 | 2003-03-04 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
JP4694745B2 (ja) * | 1999-09-07 | 2011-06-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07505372A (ja) | 3−o−脱アシル化モノホスホリル脂質a含有の肝炎ワクチン | |
JP4028593B2 (ja) | 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物 | |
KR100287083B1 (ko) | B형 간염 표면 항원 및 다른 항원을 포함하는 조합 백신 | |
JP3901731B2 (ja) | サポニンおよびステロールを含有するワクチン | |
AP766A (en) | A vaccine based on hepatitis B antigen. | |
US6893644B2 (en) | Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A | |
KR20040081469A (ko) | 점막 면역 자극제로서 간염 비 바이러스 표면 항원 및결과물로서의 제제 | |
AU705739B2 (en) | A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070912 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120912 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130912 Year of fee payment: 10 |